Member Info for Wiggly

I really could not understand why we were trading at this level with all the great news received last week. We really should be trading at multiples of 1.43.

Milton reducing makes sense.

I think this will rocket when they are cleared.

FDA expedited review can be less than a week

Especially so when you have worked hand in hand with the fda during product development..

Cytiva and/or pregnancy style was mentioned?

Who else could it be?

Could it be BAMS?

Any prediction on the Share Price reaction should AVCT announce clinically validated accuracy at >99%?

I think we are likely to see new IIs buying on the open market, taking over from the traders. This is a company that is now clearly going places.

I think we can be very confident in achievement of a clinically validated LFT with high s&s.

I just don't see how Dr Al could state he was very happy with the optimised analytical performance for the final result to be a damp squid.

In addition, there must be some min performance criteria required before Lstm would agree to partner and validate. They would not agree to review and validate any and every LFT.

In addition, I just don't see BBI entertainingx never mind partnering, of they were no confident in the product performance.

Major rerate is on the cards here.

Make that 3.

3 really key comments from the interview.

1, following the cytiva optimisation, DR Al Is 'very happy with the prototype performance'
2, Based on the above, he expects demand 'to be very high indeed'
3, bbi are putting a manufacturing process in place that will enable scale up to millions per month

2 really key comments from the interview.

1, following the cytiva optimisation, DR Al Is 'very happy with the prototype performance'
2, Based on the above, he expects demand 'to be very high indeed'

Hard to believe that LTM would collaborate to validate the LFT without first reviewing the lab/s and s data.....

Big news incoming

The below is key. Of course we have an indication of the lab/development related s and s and are now proceeding to have this fully validated.

We have been working with the Liverpool School of Tropical Medicine for some time to define the target performance specifications of the saliva-based rapid test and their insight has been tremendously helpful in this regard.

We have been working with the Liverpool School of Tropical Medicine for some time to define the target performance specifications of the saliva-based rapid test and their insight has been tremendously helpful in this regard.

Why the drop?

Doesn't matter that revenues are still a couple of months out, it seems nailed on now thay they are coming.

Cornering the UK market would be great (we likely still will when validation is complete), but let's be 100% real, taking less than 20% of the US market would be transformational for avct.

With Cytiva/danaher (150b mc) as our partner I feel confident we will do very well in the US

I still think we will finish blue

I would not be surprised to see this finish blue today.

The details here go way above my intellect on the subject however, in basic terms, doesn't this research prove that the affirmers can be used in an LFT and will deliver 100% specificity and high sensitivity?

We know that the affirmers generated bind to the cv so no reason why the LFT results should differ from the results detailed in the study posted below...

A great example of how
@affimers
can be used in lateral flow devices as diagnostics and also inhibit viral protein function.

One of my favourite extracts from this document "100% specificity of the LFAs for CCHFV NP under these conditions.

Second favourite - Affimer-NP format, detecting down to 1.5 ng of recombinant CCHFV NP per 100 µL Previous study showed antibody-based antigen-capture ELISA with a LOD of 2 ng of recombinant CCHFV NP per 100 µL was suitable for the detection of native CCHFV

https://t.co/ClrUllpF83?amp=1

Very real possibility that Avct could generate significant testing revenues for years to come.

The macro is starting to drive significant potential for avct and I would not be surprised to see new IIs start to build positions here. Certainly upon positive LFT news.